A Phase II, Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo Following 12 Weeks of Treatment in Patients With Metastatic or Recurrent Renal Cell Carcinoma Who Have Had no Previous Anti-VEGF Therapy

Trial Profile

A Phase II, Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo Following 12 Weeks of Treatment in Patients With Metastatic or Recurrent Renal Cell Carcinoma Who Have Had no Previous Anti-VEGF Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Cediranib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 19 Oct 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 11 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jan 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top